April 30th 2025
Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Appraisal of the Laser Diffraction Particle-Sizing Technique
March 2nd 2005Some published articles purport to demonstrate the difficulties and problems of the laser diffraction technique without mentioning that these apparent problems are inherent in all particle-sizing techniques. This article discusses some of the advantages of using laser diffraction for particle sizing-including repeatability, ease of verification, and speed of measurement-and why it has become the preferred technique in a range of industries.
IPEC-Americas? Updated Significant Change Guide for Bulk Pharmaceutical Excipients
March 2nd 2005IPEC-Americas has just completed a major update to its significant change guideline to address current issues in the manufacture of excipient ingredients and to assist manufacturers in developing an impurity profile.
Using Extrusion-Spheronization to Develop Controlled-Release Formulations of Azithromycin
February 2nd 2005Extrusion-spheronization and pellet compression are effective means of developing first-order kinetic, controlled-release drug delivery systems of azithromycin (AZI). The authors prepared, evaluated, and optimized AZI formulations and assessed the stability of the selected formulation under accelerated storage conditions.
Toward a Generic Approach for Stress Testing of Drug Substances and Drug Products
February 2nd 2005The Impurity Profiling Group reviews stress testing according to regulatory guidance documents. The authors emphasize what should be considered for late clinical phases and for registration application dossiers.